NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad, R.I.; Nasr, C.; Bischoff, L.; Busaidy, N.L.; Byrd, D.; Callender, G.; Dickson, P.; Duh, Q.Y.; Ehya, H.; Goldner, W.; Haymart, M.; Hoh, C.; Hunt, J.P.; Iagaru, A.; Kandeel, F.; Kopp, P.; Lamonica, D.M.; McIver, B.; Raeburn, C.D.; Ridge, J.A.; Ringel, M.D.; Scheri, R.P.; Shah, J.P.; Sippel, R.; Smallridge, R.C.; Sturgeon, C.; Wang, T.N.; Wirth, L.J.; Wong, R.J.; Johnson-Chilla, A.; Hoffmann, K.G.; Gurski, L.A.

doi:10.6004/jnccn.2018.0089

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Détails

Demande d'une copie

ID Serval

serval:BIB_B5E270CD6FAF

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Périodique

Journal of the National Comprehensive Cancer Network

Auteur⸱e⸱s

Haddad R.I., Nasr C., Bischoff L., Busaidy N.L., Byrd D., Callender G., Dickson P., Duh Q.Y., Ehya H., Goldner W., Haymart M., Hoh C., Hunt J.P., Iagaru A., Kandeel F., Kopp P., Lamonica D.M., McIver B., Raeburn C.D., Ridge J.A., Ringel M.D., Scheri R.P., Shah J.P., Sippel R., Smallridge R.C., Sturgeon C., Wang T.N., Wirth L.J., Wong R.J., Johnson-Chilla A., Hoffmann K.G., Gurski L.A.

ISSN

1540-1413 (Electronic)

ISSN-L

1540-1405

Statut éditorial

Publié

Date de publication

12/2018

Peer-reviewed

Oui

Volume

Numéro

Pages

1429-1440

Langue

anglais

Notes

Publication types: Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Résumé

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.

Mots-clé

Antineoplastic Combined Chemotherapy Protocols/standards, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, Biomarkers, Tumor/genetics, Biomarkers, Tumor/metabolism, Carcinoma/diagnosis, Carcinoma/mortality, Carcinoma/pathology, Carcinoma/therapy, Clinical Trials as Topic, Humans, Image-Guided Biopsy/methods, Image-Guided Biopsy/standards, Medical Oncology/standards, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors/standards, Protein Kinase Inhibitors/therapeutic use, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Proto-Oncogene Proteins B-raf/genetics, Societies, Medical/standards, Thyroid Gland/diagnostic imaging, Thyroid Gland/pathology, Thyroid Gland/surgery, Thyroid Neoplasms/diagnosis, Thyroid Neoplasms/genetics, Thyroid Neoplasms/pathology, Thyroid Neoplasms/therapy, Thyroidectomy/methods, Thyroidectomy/standards, Treatment Outcome, United States

OAI-PMH

oai:serval.unil.ch:BIB_B5E270CD6FAF

DOI

10.6004/jnccn.2018.0089

Pubmed

30545990

Web of science

000453034100006

Open Access

Oui

Création de la notice

16/12/2020 22:51